Rezolute

Behind each #raredisease journey is a nurse who advocates for patients at every step. Today, we recognize the nurses whose dedication improves patient outcomes and strengthens the entire care continuum. Thank you for the compassion, expertise, and steady support you provide.

We're honored to support Neuroendocrine Cancer Awareness Network's March patient conferences in Miami and Nashville, which provide vital forums for connecting patients, caregivers, and leading experts in #neuroendocrinecancer care. Register today: bit.ly/4bgp9Bw

During #MedicalGeneticsAwarenessWeek, we are proud to recognize the medical genetics community dedicated to transforming complexity into clarity and improving therapeutic decision-making for families impacted by #hyperinsulinism. Get involved: bit.ly/4blrGZX

This week, we're excited to connect with the investment community at the @CitizensBank Life Sciences Conference in Miami to discuss our #congenitalHI and #tumorHI programs. Investors interested in scheduling a meeting should contact their Citizens representative. #Rezolute

#Raredisease research demands resilience. Progress is rarely linear, and every breakthrough is hard-earned. Today, we recognize the incredible professionals who stay committed to the #Rezolute mission. Thank you for the unwavering dedication and passion you bring each day!

This Saturday, March 7, don't miss @NCFCancer's LA screening of Zeal for Life, a documentary highlighting how patients, caregivers, clinicians, and advocacy partners work together to better navigate #neuroendocrine cancer. Register for free tickets: ncf.net/events/zeal

When innovation meets ultra-rare disease, one size doesn't fit all. In a sponsored STAT article, Nevan Charles Elam explores whether placebo-controlled trials (RCTs) are the gold standard for demonstrating therapeutic benefit in ultra-rare disease. More: bit.ly/4ktxHbh

We were honored to attend the @congenitalhi CRN meeting, which brought together leading #congenitalHI advocates, researchers, and clinical professionals. We're grateful to those who came together in support of improving care and outcomes for the #hyperinsulinism community.

Huge thanks to Heather Davis from @NCFCancer for joining our team for an insightful conversation during Rare Disease Month. We’re proud to support NCF’s mission to raise awareness, accelerate diagnosis, and improve patient care. Learn more: ncf.net

1 in 10 people are affected by rare diseases. That's not rare at all. Rezolute is committed to advancing solutions for patients with rare conditions because we believe rarity shouldn't be a barrier to care; it should be a call to action. Learn more: bit.ly/3OmZq0Z

As #RareDiseaseDay approaches on February 28, we unite in recognition, advocacy, and hope. Rezolute is proud to be a corporate council member of @RareDiseases, which works to improve access to care for rare diseases like #congenitalHI and #tumorHI. #ShowYourStripes

Caregiving isn't just a duty, it's an act of love. On #NationalCaregiversDay, Rezolute recognizes the critical role caregivers play throughout the patient journey. If you're a caregiver, know that your work is valued and your wellbeing matters. #Rezolute #raredisease

Today we spotlight our disease focus area: #Hyperinsulinism (HI). HI is a rare disorder that can cause #hypoglycemia due to overstimulation of the insulin receptor, and it has serious implications for both pediatric and adult patients. Learn more: bit.ly/3OmZq0Z

Today we shared our fiscal Q2 2026 earnings report, recapping our recent progress and highlighting next steps for our #congenitalHI and #tumorHI programs. We look forward to sharing additional milestones in the months to come. Read the full release: bit.ly/4aqN0N1

We’re excited to attend the @GuggenheimPtnrs Emerging Outlook: Biotech Summit 2026 this week! We look forward to connecting with the #biotech investment community to discuss the latest in our #congenitalHI and #tumorHI programs. #BiotechSummit #Investors #Rezolute

Are randomized placebo-controlled trials the gold standard for demonstrating therapeutic benefit in patients suffering from ultra-rare diseases? Rezolute CEO Nevan Charles Elam contributed a sponsored STAT News article exploring this question. Article: bit.ly/4ktxHbh

This #WorldCancerDay, we embrace the 2025-2027 theme: "United by Unique." At Rezolute, we're dedicated to understanding individual patient needs and developing solutions that honor the uniqueness of every journey. Learn more: bit.ly/3OmZq0Z

‼️Breaking News: Rare Pediatric Disease PRV Program Reauthorized by Congress! After a two-year campaign to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, the rare disease community’s relentless advocacy has paid off. Congress has passed the Labor, HHS, and Related Agencies Appropriations bill, effectively reauthorizing the PRV Program for five years while also funding a number of other critical healthcare agencies. We applaud the reauthorization of the PRV Program and renewed investments in critical health research and public health programs. Thank you to the congressional champions who have partnered with our rare disease community to secure these advances. While significant work remains to enable all those living with rare diseases to thrive, today’s progress will accelerate innovation, expand access to life-changing therapies, and offer renewed hope to children and families whose futures once seemed beyond reach. To learn more about the full healthcare package, please visit our website: everylifefoundation.org/congress-passe…

Patients are the driving force behind everything we do. On #NationalPatientDay, we're recommitting to listening, advocating, and delivering solutions that address real patient needs. Meaningful innovation starts when we center the patient voice in every decision we make.

Our team at #JPM2026 joined Brian Buntz of @DrugDiscoverDev to discuss ersodetug as a potential treatment for people living with #hyperinsulinism (HI). Check out the full article: bit.ly/4qwbZp4